Protection you can count on for every phase of cataract surgery.

The first and only viscous dispersive, DisCoVisc® OVD provides the flexibility of both cohesive and dispersive properties in a single syringe. DisCoVisc® OVD combines the excellent endothelial protection of chondroitin sulfate with the mechanical protection of superior space maintenance and clarity.

To see how DisCoVisc® OVD can help protect your outcomes, visit AlconOVD.com.

Please see reverse for important information.
DisCoVisc® OVD outperforms other single viscoelastics during each phase of the procedure\textsuperscript{1}

Why did 97% of surgeons choose DisCoVisc® OVD compared to 35% for Healon®* in over satisfaction?\textsuperscript{1}

**RETENTION** during lens removal (phaco) phase\textsuperscript{2}

**SPACE MAINTENANCE** during capsulorhexis, and IOL insertion phases\textsuperscript{1}

**VISUALIZATION** during all phases of the procedure\textsuperscript{1}


**Caution**: Federal (USA) law restricts this device to sale by or on the order of a physician. **Description**: DisCoVisc® Ophthalmic Viscosurgical Device has an intermediate cohesive/dispersive index (CDI) and can best be described as the first viscous dispersive viscoelastic and is optimized for the entire surgical procedure. **Indications**: DisCoVisc® Ophthalmic Viscosurgical Device is indicated for use during surgery in the anterior segment of the eye. It is designed to create and maintain space, to protect the corneal endothelium and other intraocular tissues and to manipulate tissues during surgery. It may also be used to coat intraocular lenses and instruments during cataract extraction and IOL insertion. **Warnings**: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury. **Precautions**: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material. **Adverse Reactions**: DisCoVisc® Ophthalmic Viscosurgical Device was very well tolerated in nonclinical and clinical studies. A transient rise in intraocular pressure in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to affect such a rise. It is therefore recommended that DisCoVisc® OVD be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber. **ATTENTION**: Refer to the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions.